References
- Consensus Development Conference. Diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646–50
- Albright F, Smith P H, Richardson A M. Postmenopausal osteoporosis. J Am Med Assoc 1941; 116: 2465–74
- Devogelaer J P, Boutsen Y, Nagant de Deuxchaisnes C. A randomized controlled trial of ADP given intravenously with and without sodium fluoride in involutional osteoporosis. Osteoporosis, C Christiansen, K Overgaard. Osteopress, Copenhagen 1990; 1504–6
- Reginster J-Y, Caulin F, Huyghe C, . Bone effect of intermittent cyclical calcitonin and intermittent cyclical fluoride and calcitonin in the treatment of postmenopausal osteoporosis. Osteoporosis, C Christiansen, K Overgaard, et al. Osteopress, Copenhagen 1990; 1495–6
- Gambacciani M, Spinetti A, Cappagli A, et al. Effects of low-dose monofluorophosphate and transdermal oestradiol in postmenopausal vertebral bone loss. Eur Men J 1995; 2(2)16–20
- Kicovic P M, Cortes-Prieto J, Luisi M, et al. Placebo-controlled cross-over study of effects of Org OD14 in postmenopausal women. Reproduction 1982; 6: 81–91
- Benedek-Jaszmann L J. Long-term placebo-controlled efficacy and safety study of Org OD14 in climacteric women. 1987; 25–33, Maturitas;Suppl 1
- Lindsay R, Hart D M, Kraszewsky A. Prospective double-blind trial of synthetic steroid (Org OD14) for preventing postmenopausal osteoporosis. Br Med J 1980; 280: 1207–9
- Rymer J, Chapman M G, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314–9
- Bjarnason N, Bjarnason K, Haarbo J, et al. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996; 81: 2419–22
- Berning B, v. Kuijk C, Kuiper J W, et al. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two year randomized placebo controlled study. Bone 1996; 19(4)395–9
- Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD14) in women with established osteoporosis. Maturitas 1991; 13: 155–62
- Studd J, Arnala I, Kicovic P M, et al. A randomised study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures. Obstet Gynecol 1998; 92(4)574–9
- Punnonen R, Liukko P, Cortel-Prieto J, et al. Multicentre study of effects of Org OD14 on endometrium, vaginal cytology and cervical mucus in postmenopausal and oophorectomized women. Maturitas 1984; 5: 281–6
- Genazzani A R, Benedek-Jaszmann L J, Hart D M, et al. Org OD14 and the endometrium. Maturitas 1991; 13: 243–51
- Reginster J-Y, Denis D, Deroisy R, et al. Dual photon absorptiometry of lumbar spine in west European (Belgian) postmenopausal females: normal range and fracture threshold. Clin Rheumatol 1990; 9(2)220–4
- Reginster J-Y, Janssen C, Deroisy R, et al. Bone mineral density of the spine and the hip measured with dual energy X-ray absorptiometry: normal range and fracture treshold for Western European (Belgian) postmenopausal females. Cain. Rheumatol 1995; 14(1)68–75
- Mamelle N, Meunier P J, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 2: 361–5
- Riggs B L, Hodgson S F, O'Fallon W M, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322: 802–9
- Heaney R P, Baylink D J, Johnston C C, et al. Fluoride therapy for the vertebral crush fracture syndrome. Ann Intern Med 1989; 111: 678–80
- Compston J E, Yamaguchi K, Croucher P I, et al. The effects of gonadotropin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis. Bone 1995; 16(2)261–7